Quote:Comey screwed up big time
BY BRUCE UDOLF
OCTOBER 29, 2016 7:51 PM
Republicans immediately consumed with gusto Friday’s news that FBI Director James Comey sent a letter to Congressional leaders informing them that his agency was reviewing new information relating to the Hillary Clinton email case.
They gleefully declared that the FBI had “reopened” the email investigation. While this is a misleading exaggeration of Comey’s admittedly vague letter, the political use that GOP partisans have made of it illustrates why public releases of information relating to pending investigations of public figures up for election have traditionally been withheld.
When I served as chief of the Public Corruption/Integrity Section of the U.S. Attorney’s Office in Miami, there was an unwritten policy at the Justice Department that no public actions be taken with respect to any investigation involving a public figure within six months prior to an election in which that figure stood as a candidate.
This meant it was verboten for a prosecutor to seek an indictment, authorize a search warrant, issue a press release or take action that would likely be made public in the months prior to an election. The reason for this protocol was clear and simple.
Investigations of public corruption, like all other investigations, are designed to determine the truth about allegations of criminal conduct and, if justified, to serve as a basis for criminal charges — and not to influence elections.
To the extent that such disclosure might have such an unintended effect, the policy required us to stand down from such action until after the election. If the public figure were elected in the meantime, and if charges were subsequently brought and resulted in a conviction, there would be sufficient mechanisms in place to remove him or her from office.
The concept reflected in this policy is that the Department of Justice is not in the business of doing opposition research for political opponents of public figures ...
http://www.miamiherald.com/opinion/op-ed/arti...98437.html
Comey screwed up big time BY BRUCE UDOLF OCTOBER
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Lumexa Imaging's Investor Conference Push: Any Real Substance?
Lumexa Imaging just dropped a line on Feb 17, 2026, about their upcoming investor conference gigs. Sure, they're strutting into multiple events—Raymond James in Orlando, Leerink Partners in Miami, and Barclays back-to-back days after that. But here’s the kicker: are these talks really worth the buzz? In a space where outpatient imaging claims to be kingpin, you’ve...
Continue Reading
Current Landscape of US Stock Futures Amid Rate Cuts
Insights on the Current Stability of U.S. Stock Futures During Asian trading hours, U.S. stock index futures have held steady. Investors are hoping for interest rate cuts as the Federal Reserve's next meeting approaches. This meeting is expected to reveal a significant easing cycle that many in the market are eagerly anticipating. Even with strong reports on consumer and...
Continue Reading
Wispr Flow Revolutionizes Voice Dictation Across Platforms
Wispr Flow Expands Its Reach in Voice Dictation Technology In a world where speed and efficiency are paramount, Wispr, known as The Voice Interface Company, is revolutionizing the way we interact with technology. With the recent launch of Wispr Flow for Windows, this innovative voice productivity tool is now accessible to users across both Mac and Windows platforms,...
Continue Reading
MintMiner: Your Ultimate Gateway to Cloud Mining Success
Unlocking the Future of Cloud Mining with MintMiner In today's uncertain financial landscape, MintMiner presents an innovative solution for anyone looking to tap into the world of digital assets. As global financial systems face challenges, MintMiner offers a unique platform that makes cloud mining accessible, straightforward, and profitable. Understanding Cloud Mining...
Continue Reading
GT Biopharma's Strategic Move: Withdrawal of S-1 Registration
GT Biopharma's Strategic Withdrawal of Form S-1 Registration GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with its request for withdrawal of a Form S-1 registration statement. This decision marks a crucial moment for the company, based in San Francisco, known for its innovative approach in the immuno-oncology sector. GT Biopharma focuses on the development of...
Continue Reading